Commentary

Video

Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma

Author(s):

David M. Siegel, MD, PhD
Conference|ASH Annual Meeting and Exposition

David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.

David Samuel Dicapua Siegel, MD, chief, Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, discusses preliminary findings from the phase 1/2 CA057-003 trial (NCT05372354) evaluating the novel agent mezigdomide for patients with relapsed or refractory multiple myeloma.

Related Videos
Nosha Farhadfar, MD, and Chandler Park, MD, FACP
Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Laahn Foster, MD
Christine Mauz-Koerholz, MD, PhD
Marcella Ali Kaddoura, MD
Wojciech Jurczak, MD, PhD
Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.
Stephen V. Liu, MD
Related Content
ASH Meeting | Image credit: © Nittaya – stock.adobe.com
December 9th 2024

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Zanubrutinib in Newly Diagnosed CLL/SLL | Image Credit: © Свет Лана – stock.adobe.com
December 9th 2024

Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

Chronic Lymphocytic Leukemia | Image Credit: © LASZLO– stock.adobe.com
December 9th 2024

Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML

ASH Meeting | Image credit: ©Nittaya – stock.adobe.com
December 9th 2024

Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor–Naive Myelofibrosis